Sentinel lymph node biopsy for early stage cervical cancer.

Sentinel lymph node biopsy for early stage cervical cancer. - Sentinel lymph node biopsy for early stage cervical cancer.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029282

Enrollment

Registered

2017-10-01

Start date

2017-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical cancer

Interventions

1. Cervical injection of 99m Tc - phytate (55-70MBq) on 3-6-9-12 o`clock position. 2. Lymphoscintigraphy (15:00 the day before surgery) 3. Lymphoscintigraphy (8:00 the operation day) 4. Cervic

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Early stage (1A2-2) cervical cancer Squamous cell carcinoma, adenocarcinoma ECOG Performance Status,0-1

Exclusion criteria

Exclusion criteria: Patient with pelvic lymeph node metastasis on imaging. Pataients with severe complications. The patients who are unappropriate for this study judged by the physician.

Design outcomes

Primary

Measure	Time frame
over all survival	—

Secondary

Measure	Time frame
5 year survival progression free survival detection rate of sentinel lymph node negative predictive value	—

Countries

Japan

Contacts

Public ContactNatsuki Tsuji

Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital Department of Obstetrics and Gynecology

n-tsuzi@kitano-hp.or.jp06-6312-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026